Bausch Health Companies Inc
BHC5.725USD
+0.015+0.26%
Market hours （ET）Quotes delayed by 15 min
2.12BMarket Cap
LossP/E TTM
More Details of Bausch Health Companies Inc Company
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
Company Info
Ticker SymbolBHC
Company nameBausch Health Companies Inc
IPO dateSep 20, 1994
CEOMr. Thomas J. Appio
Number of employees20700
Security typeOrdinary Share
Fiscal year-endSep 20
Address2150 St. Elzear Blvd. West
CityLAVAL
Stock exchangeThe Toronto Stock Exchange
CountryCanada
Postal codeH7L 4A8
Phone18003611448
Websitehttps://www.bauschhealth.com/
Ticker SymbolBHC
IPO dateSep 20, 1994
CEOMr. Thomas J. Appio
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas J. Appio
Mr. Thomas J. Appio
Chief Executive Officer, Director
Chief Executive Officer, Director
627.22K
-24.81%
Dr. Amy B. Wechsler, M.D.
Dr. Amy B. Wechsler, M.D.
Independent Director
Independent Director
264.39K
+0.39%
Mr. Robert N. Power
Mr. Robert N. Power
Independent Director
Independent Director
254.72K
+27.12%
Mr. Steven D. Miller
Mr. Steven D. Miller
Independent Director
Independent Director
239.22K
+29.40%
Mr. Brett M. Icahn
Mr. Brett M. Icahn
Independent Director
Independent Director
225.40K
+1.82%
Ms. Sandra Leung
Ms. Sandra Leung
Director
Director
30.15K
--
Mr. Michael Goettler
Mr. Michael Goettler
Director
Director
30.15K
--
Ms. Aimee J. Lenar
Ms. Aimee J. Lenar
Executive Vice President, US Pharma
Executive Vice President, US Pharma
8.11K
--
Dr. Richard C. Mulligan, Ph.D.
Dr. Richard C. Mulligan, Ph.D.
Independent Director
Independent Director
--
--
Mr. John A. Paulson
Mr. John A. Paulson
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas J. Appio
Mr. Thomas J. Appio
Chief Executive Officer, Director
Chief Executive Officer, Director
627.22K
-24.81%
Dr. Amy B. Wechsler, M.D.
Dr. Amy B. Wechsler, M.D.
Independent Director
Independent Director
264.39K
+0.39%
Mr. Robert N. Power
Mr. Robert N. Power
Independent Director
Independent Director
254.72K
+27.12%
Mr. Steven D. Miller
Mr. Steven D. Miller
Independent Director
Independent Director
239.22K
+29.40%
Mr. Brett M. Icahn
Mr. Brett M. Icahn
Independent Director
Independent Director
225.40K
+1.82%
Ms. Sandra Leung
Ms. Sandra Leung
Director
Director
30.15K
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Pharmaceutical Products
4.40B
45.67%
Device Products
2.24B
23.27%
OTC
1.90B
19.77%
Branded and Other Generic Products
979.00M
10.17%
Other Product Lines
107.00M
1.11%
By RegionUSD
Name
Revenue
Proportion
United States and Puerto Rico
5.77B
59.92%
Other Foreign Countries
1.08B
11.25%
China (Country)
496.00M
5.15%
Canada
402.00M
4.18%
Poland
350.00M
3.64%
Other
1.53B
15.86%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Pharmaceutical Products
4.40B
45.67%
Device Products
2.24B
23.27%
OTC
1.90B
19.77%
Branded and Other Generic Products
979.00M
10.17%
Other Product Lines
107.00M
1.11%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Meruelo (Alex)
9.94%
Icahn Associates Corporation
9.39%
Paulson & Co. Inc.
8.87%
GoldenTree Asset Management, LP
8.18%
Nomura Securities Co., Ltd.
6.33%
Other
57.29%
Shareholders
Shareholders
Proportion
Meruelo (Alex)
9.94%
Icahn Associates Corporation
9.39%
Paulson & Co. Inc.
8.87%
GoldenTree Asset Management, LP
8.18%
Nomura Securities Co., Ltd.
6.33%
Other
57.29%
Shareholder Types
Shareholders
Proportion
Hedge Fund
16.44%
Investment Advisor/Hedge Fund
16.30%
Individual Investor
11.04%
Family Office
8.87%
Research Firm
8.65%
Investment Advisor
8.64%
Bank and Trust
4.41%
Pension Fund
4.26%
Private Equity
1.42%
Other
19.98%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
514
263.21M
71.22%
-46.16M
2025Q1
547
263.71M
71.37%
-49.89M
2024Q4
568
275.73M
74.96%
-32.06M
2024Q3
627
279.89M
77.25%
-44.78M
2024Q2
703
283.62M
78.54%
-59.67M
2024Q1
764
278.87M
76.11%
-93.72M
2023Q4
801
283.62M
78.55%
-85.16M
2023Q3
821
301.23M
82.72%
-52.06M
2023Q2
836
283.61M
80.53%
-76.52M
2023Q1
862
290.05M
79.80%
-77.57M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Meruelo (Alex)
36.76M
9.95%
+148.73K
+0.41%
Mar 31, 2025
Icahn Associates Corporation
34.72M
9.4%
--
--
May 20, 2025
Paulson & Co. Inc.
32.79M
8.87%
+6.35M
+24.03%
Jun 13, 2025
GoldenTree Asset Management, LP
30.25M
8.19%
+2.71M
+9.84%
Mar 31, 2025
Nomura Securities Co., Ltd.
23.39M
6.33%
+12.05M
+106.21%
Mar 31, 2025
Healthcare Of Ontario Pension Plan
13.00M
3.52%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
11.68M
3.16%
+61.62K
+0.53%
Mar 31, 2025
National Bank of Canada
7.51M
2.03%
-7.91M
-51.29%
Mar 31, 2025
Maple Rock Capital Partners, Inc.
6.80M
1.84%
+1.50M
+28.25%
Mar 31, 2025
Macquarie Investment Management Global Ltd.
6.60M
1.79%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Gotham 1000 Value ETF
0.18%
VanEck Pharmaceutical ETF
0.14%
FlexShares Morningstar Developed Markets ex-US Factor Tilt Index ETF
0.12%
JPMorgan International Value ETF
0.09%
Schwab International Small-Cap Equity ETF
0.08%
iShares Intl Small Cap Equity Factor ETF
0.06%
DFA Dimensional International Small Cap ETF
0.05%
Schwab Fundamental International Equity ETF
0.04%
Invesco RAFI Developed Mkts ex-US ETF
0.03%
DFA Dimensional Intl Sustainability Core 1 ETF
0.01%
View more
Gotham 1000 Value ETF
Proportion0.18%
VanEck Pharmaceutical ETF
Proportion0.14%
FlexShares Morningstar Developed Markets ex-US Factor Tilt Index ETF
Proportion0.12%
JPMorgan International Value ETF
Proportion0.09%
Schwab International Small-Cap Equity ETF
Proportion0.08%
iShares Intl Small Cap Equity Factor ETF
Proportion0.06%
DFA Dimensional International Small Cap ETF
Proportion0.05%
Schwab Fundamental International Equity ETF
Proportion0.04%
Invesco RAFI Developed Mkts ex-US ETF
Proportion0.03%
DFA Dimensional Intl Sustainability Core 1 ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
